Hyperglycemia and cardiovascular disease in type 2 diabetes

Diabetes

Volumn 48, Issue 5, 1999, Pages 937-942

  Laakso, Markku ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; PHENFORMIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032908858     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.5.937     Document Type: Review

References (50)

1. Pyörälä K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463-524, 1987
2. Laakso M, Lehto S: Epidemiology of macrovascular disease in diabetes. Diabetes Rev 5:294-315, 1997
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
4. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898, 1990
5. WHO Expert Committee on Diabetes Mellitus: Second Report. Geneva, World Health Org., 1980 (Tech. Rep. Ser., no. 646)
6. Hunter SJ, Garvey TW: Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 105:331-345, 1998
7. Fajans SS, Bell GI, Bowden DW, Halter JB, Polonsky KS: Maturity-onset diabetes of the young. Life Sci 55:413-422, 1994
8. Keen H, Rose G, Pyke DA, Boyns D, Chlouverakis C, Mistry S: Blood-sugar and arterial disease. Lancet 2:505-508, 1965
9. Ostrander LD, Francis T, Hayner NS, Kjesberg MO, Epstein FH: The relationship of cardiovascular disease to hyperglycemia. Ann Intern. Med 62: 1188-1198, 1965
10. International Collaborative Group: Asymptomatic hyperglycemia and coronary heart disease: a series of papers by the International Collaborative Group based on studies in fifteen populations. J Chronic Dis 32:829-837, 1979
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240, 1999
12. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwege E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care 21:360-366, 1998
13. Uusitupa MIJ, Niskanen LK, Voutilainen E, Pyörälä K: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 36:1175-1184, 1993
14. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 43:960-967, 1994
15. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 25:1157-1164, 1994
16. Andersson DKG, Svärdsudd K: Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
17. Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268, 1995
18. Gall M-A, Borch-Johnsen K, Hougaard P, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309, 1995
19. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelash HJ, Lindner J, the DIS Group: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study: 11-year follow-up. Diabetologia 39:1577-1583, 1996
20. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39:1540-1545, 1996
21. Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Predictors of stroke in middle-aged patients with non-insulin dependent diabetes. Stroke 27:63-68, 1996
22. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 48:1354-1359, 1997
23. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR, for the United Kingdom Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828, 1998
24. Wei M, Gaskill SP, Haffner SM, Stern MP: Effect of diabetes and level of glycemia on all-cause and cardiovascular mortality: the San Antonio Heart Study. Diabetes Core 21:1167-1172, 1998
25. Meigs JB, Singer DE, Sullivan LM, Dukes KA, D'Agostino RB, Nathan DM, Wagner EH, Kaplan SH, Greenfield S: Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research team. Am J Med 102:38-47, 1997
26. Niskanen L, Turpeinen A, Penttilä I, Uusitupa MI: Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care 21:1861-1869, 1998
27. Bayes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
28. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101:1905-1915, 1998
29. Vlassara H: Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 (Suppl. 2);S19-S25, 1997
30. Lyons TJ: Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 71:26B-31B, 1993
31. Giugliano D, Ceriello A, Paolisso G: Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 44:363-368, 1995
32. Park L, Raman KG, Lee KJ, Lu Y, Ferran JL Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031, 1998
33. Koya D, King GL: Protein kinase C and the development of diabetic complications. Diabetes 47:859-866, 1998
34. Heaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473-486, 1995
35. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M: Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest 101:86-96, 1998
36. Jarrett JR: Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease: chicken, egg, or neither? Diabetologia 26:99-102, 1984
37. Stern MP: Diabetes and cardiovascular disease: the 'common soil' hypothesis. Diabetes 44:369-374, 1995
38. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
39. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG: Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Mortality and selected nonfatal events with insulin treatment JAMA 240:37-42, 1978
40. Colwell JA, Clark CM: Forum two: unanswered research questions about metabolic control in non-insulin dependent diabetes mellitus. Ann Intern Med 124:178-179, 1996
41. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenström A, Wedel H, of the DIGAMI Study Group: Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 17:1337-1344, 1996
42. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
43. Laakso M: Benefits of strict glucose and blood pressure control in type 2 diabetes: lessons from the UK Prospective Diabetes Study. Circulation 99:461-462, 1999
44. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
45. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
46. Pyörälä K, Pedersen TR, Kjekshus J, Kjekshus J, Faergeman O, Olsson A, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20:614-620, 1997
47. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
48. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) 7Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
49. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 21:160-178, 1998
50. Laakso M: Epidemiology of diabetic dyslipidemia Diabetes Rev 3:408-422, 1995